International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting Highlights

Strategic Insights -

The 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc) took place in San Diego, CA, on October 30, 2008. The meeting covered various topics in tumor immunology and immunotherapy, including cytokines in cancer immunology, anti-angiogenic therapy, and immune monitoring of cancer immunotherapy. The event was attended by internationally renowned investigators who presented their research on the latest advances in biologic therapies. The goal of the meeting was to provide a primer course for attendees from academic, regulatory, and biopharmaceutical venues, enabling them to learn the current status and most recent advances in biologic therapies to improve cancer therapy.

Key Takeaways:

  • The International Society for Biological Therapy of Cancer (iSBTc) is a premier destination for interaction and innovation in the cancer biologics community.
  • The annual meeting provides a primer course to address the most important areas of tumor immunology and immunotherapy, covering core principles of cancer immunology and immunotherapy.
  • The target audience for the program includes investigators from academic, regulatory, and biopharmaceutical venues.
  • The 2008 immunologic primer course was conducted by nine internationally renowned investigators who presented on different topics, including cytokines, anti-angiogenic therapy, and immune monitoring of cancer immunotherapy.
  • The meeting aimed to enable attendees to learn the current status and most recent advances in biologic therapies and leverage this knowledge towards the improvement of cancer therapy.
  • The program included topics such as approach to identification and therapeutic exploitation of tumor antigens, T regulatory cells, adoptive T cell therapy, and immune adjuvants.
  • The related topic slides and schedule can be accessed online at http://www.isbtc.org/meetings/am08/primer08.

Statistics:

  • The 23rd Annual Meeting of iSBTc was held on October 30, 2008, in San Diego, CA.
  • Nine internationally renowned investigators presented their research on different topics at the 2008 immunologic primer course.
  • The topics covered in the primer included: (1) cytokines in cancer immunology; (2) anti-angiogenic therapy; (3) end stage: immune killing of tumors; (4) blocking T cell checkpoints; (5) approach to identification and therapeutic exploitation of tumor antigens; (6) T regulatory cells; (7) adoptive T cell therapy; (8) immune monitoring of cancer immunotherapy; and (9) immune adjuvants.

Sources:

  • "The International Society for Biological Therapy of Cancer (iSBTc) is one of the 'premier destinations for interaction and innovation in the cancer biologics community'."

+ Source: Study from the United States

  • Li, Y.F., et al. (2009). Summary of the primer on tumor immunology and the biological therapy of cancer. Journal of Translational Medicine, 7():11.

+ Source: Journal of Translational Medicine

  • Biomedical Central Ltd. (Publisher of the Journal of Translational Medicine)

+ Source: Current Science Group, Middlesex House, 34-42 Cleveland St., London W1T 4LB, England